Tela Bio Ownership
| TELA Stock | USD 1.08 0.09 9.09% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 24.7 M | Current Value 40.1 M | Avarage Shares Outstanding 15.1 M | Quarterly Volatility 8.7 M |
Tela Stock Ownership Analysis
About 68.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.38. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tela Bio recorded a loss per share of 1.33. The entity had not issued any dividends in recent years. TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patients anatomy. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Tela Bio operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 123 people. To find out more about Tela Bio contact the company at 484 320 2930 or learn more at https://www.telabio.com.Tela Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tela Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tela Bio backward and forwards among themselves. Tela Bio's institutional investor refers to the entity that pools money to purchase Tela Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citigroup Inc | 2024-12-31 | 750 K | Sio Capital Management, Llc | 2024-12-31 | 630 K | Blackrock Inc | 2024-12-31 | 427.5 K | Renaissance Technologies Corp | 2024-12-31 | 425.1 K | Mink Brook Asset Management Llc | 2024-12-31 | 357.1 K | Geode Capital Management, Llc | 2024-12-31 | 311.4 K | Archon Capital Management Llc | 2024-12-31 | 150 K | Gsa Capital Partners Llp | 2024-12-31 | 135.8 K | Jpmorgan Chase & Co | 2024-12-31 | 133.7 K | Essex Woodlands Health Ventures | 2024-12-31 | 4.1 M | Nantahala Capital Management, Llc | 2024-12-31 | 3.7 M |
Tela Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tela Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tela Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tela Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tela Bio Outstanding Bonds
Tela Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tela Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tela bonds can be classified according to their maturity, which is the date when Tela Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TD AMERITRADE HLDG Corp BondUS87236YAF51 | View | |
| US87236YAJ73 Corp BondUS87236YAJ73 | View | |
| US87233QAC24 Corp BondUS87233QAC24 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tela Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tela Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tela Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tela Bio Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tela Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tela Bio. If investors know Tela will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tela Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.038 | Return On Assets | Return On Equity |
The market value of Tela Bio is measured differently than its book value, which is the value of Tela that is recorded on the company's balance sheet. Investors also form their own opinion of Tela Bio's value that differs from its market value or its book value, called intrinsic value, which is Tela Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tela Bio's market value can be influenced by many factors that don't directly affect Tela Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tela Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tela Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tela Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.